S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
NASDAQ:PHAT

Phathom Pharmaceuticals - PHAT Stock Forecast, Price & News

$7.25
+0.21 (+2.98%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$6.84
$7.28
50-Day Range
$6.20
$10.40
52-Week Range
$6.09
$37.17
Volume
281,200 shs
Average Volume
197,108 shs
Market Capitalization
$284.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.75

Phathom Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
475.9% Upside
$41.75 Price Target
Short Interest
Bearish
16.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Phathom Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Acquiring Shares
$415,105 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

911th out of 1,283 stocks

Pharmaceutical Preparations Industry

436th out of 615 stocks

PHAT stock logo

About Phathom Pharmaceuticals (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals Stock Performance

NASDAQ:PHAT opened at $7.25 on Monday. The company has a debt-to-equity ratio of 2.39, a current ratio of 9.93 and a quick ratio of 12.79. Phathom Pharmaceuticals has a 1 year low of $6.09 and a 1 year high of $37.17. The company has a market capitalization of $284.02 million, a PE ratio of -1.67 and a beta of 0.75. The company has a fifty day moving average of $8.33 and a two-hundred day moving average of $12.15.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($1.07) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. The Goldman Sachs Group lowered their target price on shares of Phathom Pharmaceuticals from $15.00 to $9.00 and set a "neutral" rating for the company in a research note on Wednesday, August 3rd. Needham & Company LLC lowered their target price on shares of Phathom Pharmaceuticals from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Wednesday, August 3rd. Finally, BMO Capital Markets decreased their price objective on shares of Phathom Pharmaceuticals from $54.00 to $45.00 in a research note on Wednesday, August 3rd.

Insider Transactions at Phathom Pharmaceuticals

In other Phathom Pharmaceuticals news, COO Azmi Nabulsi bought 20,000 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was acquired at an average price of $8.16 per share, for a total transaction of $163,200.00. Following the completion of the purchase, the chief operating officer now owns 785,700 shares of the company's stock, valued at $6,411,312. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other Phathom Pharmaceuticals news, COO Azmi Nabulsi bought 20,000 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was acquired at an average price of $8.16 per share, for a total transaction of $163,200.00. Following the completion of the purchase, the chief operating officer now owns 785,700 shares of the company's stock, valued at $6,411,312. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Asit Parikh bought 12,500 shares of the firm's stock in a transaction dated Thursday, May 12th. The shares were acquired at an average price of $8.00 per share, with a total value of $100,000.00. Following the purchase, the director now directly owns 12,500 shares of the company's stock, valued at approximately $100,000. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 53,000 shares of company stock worth $415,105. Company insiders own 7.50% of the company's stock.

Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Stock News Headlines

Nasdaq Turns Positive; Crude Oil Moves Higher
Phathom Pharmaceuticals, Inc. (PHAT)
FDA Accepts Review Of Phathom Pharmaceuticals' NDA For Vonoprazan
See More Headlines
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Company Calendar

Last Earnings
5/10/2022
Today
8/07/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.75
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+475.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-143,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.18) per share

Miscellaneous

Free Float
36,237,000
Market Cap
$284.02 million
Optionable
Not Optionable
Beta
0.75














PHAT Stock - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Phathom Pharmaceuticals stock.
View analyst ratings for Phathom Pharmaceuticals
or view top-rated stocks.

What is Phathom Pharmaceuticals' stock price forecast for 2022?

3 Wall Street research analysts have issued 1 year price targets for Phathom Pharmaceuticals' shares. Their PHAT stock forecasts range from $9.00 to $75.00. On average, they predict Phathom Pharmaceuticals' share price to reach $41.75 in the next twelve months. This suggests a possible upside of 475.9% from the stock's current price.
View analysts' price targets for Phathom Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Phathom Pharmaceuticals' stock price performed in 2022?

Phathom Pharmaceuticals' stock was trading at $19.67 at the beginning of 2022. Since then, PHAT stock has decreased by 63.1% and is now trading at $7.25.
View the best growth stocks for 2022 here
.

When is Phathom Pharmaceuticals' next earnings date?

Phathom Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our earnings forecast for Phathom Pharmaceuticals
.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) posted its quarterly earnings data on Tuesday, May, 10th. The company reported ($1.07) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Medicxi Ventures Management Jersey Ltd (6.27%), Mirae Asset Global Investments Co. Ltd. (0.23%), Chartwell Investment Partners LLC (0.17%), Hennion & Walsh Asset Management Inc. (0.14%), Occidental Asset Management LLC (0.08%) and Inspirion Wealth Advisors LLC (0.06%). Company insiders that own Phathom Pharmaceuticals stock include Asit Parikh, Azmi Nabulsi, David A Socks, Life Sciences Ix LP Frazier, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda, Ra Capital Management, LP and Terrie Curran.
View institutional ownership trends for Phathom Pharmaceuticals
.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $7.25.

How much money does Phathom Pharmaceuticals make?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a market capitalization of $284.02 million. The company earns $-143,880,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis.

How many employees does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals employs 77 workers across the globe.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The official website for Phathom Pharmaceuticals is www.phathompharma.com. The company can be reached via phone at 877-742-8466 or via email at ir@phathompharma.com.

This page (NASDAQ:PHAT) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.